AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03401437 — intervention group
Intervention type: BEHAVIORAL
Intervention: SF-36
Description: Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab-matching placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone-matching placebo
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Study NCT00915239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg pantoprazole once daily for 28 days
Study NCT00915239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo once daily for 28 days
Study NCT01747785 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
Study NCT01181102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban
Study NCT01181102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin sodium
Study NCT04753047 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00741455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.
Study NCT00741455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day on days 5, 6, and 7
Study NCT00741455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/d IV over 30 minutes on days -6 to -2
Study NCT00741455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1 g/m2/d IV on days -3 and -2
Study NCT00741455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
Study NCT00741455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
Study NCT02799134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02799134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Study NCT02799134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Study NCT00788034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Description: 5 or 10 mg/day
Study NCT00788034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT03242460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG
Description: Pomalidomide 4mg Days 1-21
Study NCT03242460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20mg
Description: Dexamethasone 20mg Days 1, 8, 15, 22
Study NCT03242460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 400mg
Description: Cyclophosphamide 400mg Days 1, 8, 15
Study NCT04671030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine and Glycopyrrolate
Description: Intravenous followed by transdermal administration of the two drug combination.
Study NCT04671030 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoresis
Description: Application of direct current to skin using an FDA-approved device
Study NCT04671030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Application of direct current to skin using an FDA-approved device
Study NCT02567318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-scan
Description: Magnetic resonance imaging scan of the brain
Study NCT03134443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Andrographolide sulfonate
Description: Routine treatment for acute tonsillitis + Xiyanping injection
Study NCT03134443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Andrographolide sulfonate simulation
Description: Routine treatment for acute tonsillitis + Xiyanping injection simulation
Study NCT03869203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Description: The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
Study NCT04414306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person cancer screening education
Description: Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
Study NCT04414306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video and website module
Description: Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
Study NCT04414306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video
Description: Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
Study NCT04414306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Message from healthcare system and online educational video and website module
Description: Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: KYMRIAH
Description: FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: YESCARTA
Description: CD19-directed genetically modified autologous T cell immunotherapy
Study NCT01226849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, rituximab, ifosphamide, etoposide, carboplatin
Description: Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
Study NCT02555215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: administered orally
Study NCT02928354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - AZD7594
Description: Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
Study NCT02928354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD7594
Description: Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
Study NCT02928354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - AZD7594
Description: Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
Study NCT03451721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReady™ MR Conditional Defibrillation System
Description: Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
Study NCT03237975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be the Expert for Your Own (BEYO)
Description: The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan.
Study NCT03401437 — intervention group
Intervention type: BEHAVIORAL
Intervention: HAD
Description: Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
Study NCT03401437 — intervention group
Intervention type: OTHER
Intervention: ANSM
Description: Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
Study NCT02782442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Cognitive Training & PRIME
Description: The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
Study NCT02782442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Games Control & PRIME
Description: Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
Study NCT02665533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone-matching placebo
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:tablets Route of administration: oral administration
Study NCT02665533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium associated with Codeine
Description: Diclofenac Sodium 50 mg associated with Codeine 50 mg
Study NCT03600818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:tablets Route of administration: oral administration
Study NCT03392181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
Study NCT02318017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Before neurocognitive testing, Methylphenidate/Placebo will be given
Study NCT02318017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04046393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Taiwan Scientific noninvasive blood pressure meter TS-0411
Description: measure autonomic nerve
Study NCT04046393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan Scientific noninvasive blood pressure meter TS-0411
Description: measure autonomic nerve
Study NCT04046393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Meridian Energy Analysis Device(MEAD)
Description: measure meridian energy
Study NCT04046393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meridian Energy Analysis Device(MEAD)
Description: measure meridian energy
Study NCT04046393 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bacteria culture
Description: use culture swab to culture nasal discharge
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 4 doses
Description: 30 mg/m2 IV daily for 4 doses
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide 500 mg/m2; 2 doses
Description: 500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
Study NCT03642626 — intervention group
Intervention type: DRUG
Intervention: Fludarabine 30mg/m2 3 doses
Description: 30 mg/m2 IV daily for 3 doses
Study NCT04046393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bacteria culture
Description: use culture swab to culture nasal discharge
Study NCT04046393 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nasopharyngoscopic examination
Description: use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
Study NCT03237975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine health education
Description: The control group will receive routine health education.
Study NCT01602159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Bypass Surgery
Description: Open Bypass Surgery with Autogenous vein or PTFE Graft
Study NCT01602159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty and Stenting
Description: Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
Study NCT03831399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine
Description: Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
Study NCT03831399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
Study NCT02616081 — intervention group
Intervention type: OTHER
Intervention: Clean Intermittent Catheterization
Description: Clean intermittent self catheterization is a standard of care.
Study NCT04046393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasopharyngoscopic examination
Description: use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
Study NCT04046393 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TCM nasal irrigation
Description: Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
Study NCT02115035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vermurafenib
Description: 960 mg of Vermurafenib twice daily orally on a 28 day schedule
Study NCT03509961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS-MRD
Description: Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
Study NCT03509961 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Description: Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant
Study NCT05192421 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: Receive wellness education through a weekly email and web portal content.
Study NCT05192421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Education
Description: Receive wellness education through a weekly email and web portal content.
Study NCT05192421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Videos
Description: Receive pre-recorded exercise videos through a weekly email and web portal content.
Study NCT05192421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Livestream Classes
Description: Receive 3 videoconference group exercise classes per week for 8 weeks.
Study NCT01012284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: 400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
Study NCT01291446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: High flatulogenic diet
Description: During 3-days subjects will consume a diet with high content of fermentable residues
Study NCT04324450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging
Study NCT04076267 — intervention group
Intervention type: OTHER
Intervention: Tool assessing symptoms validation
Description: Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
Study NCT01252615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient only
Description: education, behavioral strategies, psychological interventions
Study NCT01252615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient and partner intervention
Description: education, psychological support, behavioral strategies
Study NCT03982017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Technology Platform
Description: When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
Study NCT03982017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
Study NCT00381654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-412
Description: Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)